Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: A secondary analysis of data from two observational cohort studies

The Lancet Respiratory Medicine

Volumn 3, Issue 3, 2015, Pages 201-209

  Kurbatova, Ekaterina V ^a   Cegielski, J Peter ^a   Lienhardt, Christian ^b   Akksilp, Rattanawadee ^c   Bayona, Jaime ^d   Becerra, Mercedes C ^d   Caoili, Janice ^e   Contreras, Carmen ^f   Dalton, Tracy ^a   Danilovits, Manfred ^g   Demikhova, Olga V ^h   Ershova, Julia ^a   Gammino, Victoria M ^a   Gelmanova, Irina ^d   Heilig, Charles M ^a   Jou, Ruwen ⁱ   Kazennyy, Boris ^j   Keshavjee, Salmaan ^d   Kim, Hee Jin ^k   Kliiman, Kai ^g   Kvasnovsky, Charlotte ^a   Leimane, Vaira ^l   Mitnick, Carole D ^d   Quelapio, Imelda ^e   Riekstina, Vija ^l   Smith, Sarah E ^a   Tupasi, Thelma ^e   van der Walt, Martie ^m   Vasilyeva, Irina A ^h   Via, Laura E ⁿ   Viiklepp, Piret ^o   Volchenkov, Grigory ^p   Walker, Allison Taylor ^a   Wolfgang, Melanie ^a   Yagui, Martin ^q   Zignol, Matteo ^b   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Office of Disease Prevention and Control 7   (Thailand)

^d PARTNERS IN HEALTH   (United States)

^e Tropical Disease Foundation   (Philippines)

^f SOCIOS EN SALUD   (Peru)

^g TARTU UNIVERSITY HOSPITAL   (Estonia)

^h CENTRAL TUBERCULOSIS RESEARCH INSTITUTE   (Russian Federation)

ⁱ CENTER FOR DISEASE CONTROL   (Taiwan)

^j Orel Oblast Tuberculosis Dispensary   (Russian Federation)

^k Korean Institute of Tuberculosis   (South Korea)

^l RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^m SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

ⁿ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^o NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^p Vladimir Oblast Tuberculosis Dispensary   (Russian Federation)

^q NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BIVARIATE ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FUNDING; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; SPUTUM CULTURE CONVERSION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VALIDITY; ADOLESCENT; AGED; CLINICAL TRIAL; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDY; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; HUMANS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84924430701     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00036-3     Document Type: Article

References (27)

1. FDA news release US Food and Drug Administration (U.S.), (accessed March 13, 2014). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm.
2. Mitchison DA Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993, 147:1062-1063.
3. Wallis RS, Doherty TM, Onyebujoh P, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2009, 9:162-172.
4. Lienhardt C, Davies G Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities. Int J Tuberc Lung Dis 2010, 14:528-537.
5. Briefing information for the June 3, 2009 meeting of the Anti-Infective Drugs Advisory Committee US Food and Drug Administration, (accessed March 17, 2014). http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/ucm161856.htm.
6. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012, 380:1406-1417.
7. Gammino V, Taylor A, Rich M, et al. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis 2011, 15:1315-1322.
8. Kurbatova EV, Gammino VM, Bayona J, et al. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2012, 16:1335-1343.
9. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update WHO, (accessed March 17, 2014). http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf.
10. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLoS Med 2012, 9:e1001300.
11. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009, 4:e6914.
12. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:153-161.
13. Harbord R, Deeks J, Egger M, Whiting P, Sterne JAC A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007, 8:239-251.
14. Reitsma J, Glas A, Rutjes AWS, Scholten RJPM, Bossuyt P, Zwinderman A Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005, 58:982-990.
15. Prentice RL Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8:431-440.
16. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006, 12:1389-1397.
17. MacKenzie WR, Heilig CM, Bozeman L, et al. Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One 2011, 6:e18358.
18. Phillips PPJ, Fielding K, Nunn A An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One 2013, 8:e63840.
19. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014, 371:1577-1587.
20. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014, 371:1599-1608.
21. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014, 371:1588-1598.
22. Wallis RS, Wang C, Meyer D, Thomas N Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS One 2013, 8:e71116.
23. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update WHO, (accessed March 17, 2014). http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf.
24. Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006, 144:650-659.
25. Joseph P, Desai VB, Mohan NS, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res 2011, 133:529-534.
26. Progress report: DR-TB clinical trials Resist-TB, (accessed May 5, 2014). http://www.resisttb.org/?p=1595.
27. Phillips PPJ, Gillespie S, Boeree M, et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis 2012, 205(suppl 2):S250-S257.